A companion animal therapeutics developer has published a new study with results that demonstrate the potential of an antigen-specific immunotherapy, AKS-107, to target and delete insulin-specific ß cells. The results also show the versatility of the development platform the therapy was based on. Akston Biosciences is also working to commercialize canine and feline insulin therapies in its animal health pipeline.